Clinica Baviera, SA (ES:CBAV)
BME:CBAV
Want to see ES:CBAV full AI Analyst Report?
Top Page
Clinica Baviera
(BME:CBAV)
Select Model
Select Model
Rating:78Outperform
Price Target:
€66.00
▲(39.53% Upside)
Action:Upgraded
Date:05/31/26
The score is driven primarily by strong financial performance (durable margins, accelerating revenue, and solid cash conversion) and supportive technical strength (price above major moving averages with positive momentum). Valuation is the main moderating factor due to a mid-20s P/E, only partly balanced by the dividend yield.
Positive Factors
Revenue Growth Trajectory
Multi-year organic revenue growth with a marked TTM acceleration indicates expanding patient volumes and stronger clinic utilization. Durable top-line momentum supports scale advantages in purchasing, fixed-cost absorption and continued investment in clinical capacity over the next 2–6 months.
Negative Factors
Leverage Remains Meaningful
Although leverage has improved, absolute debt levels have not declined materially, leaving balance sheet sensitivity to slower cash flow or cyclical dips. Meaningful leverage can restrict strategic flexibility for M&A, larger capital projects or rapid share buybacks if earnings soften.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trajectory
Multi-year organic revenue growth with a marked TTM acceleration indicates expanding patient volumes and stronger clinic utilization. Durable top-line momentum supports scale advantages in purchasing, fixed-cost absorption and continued investment in clinical capacity over the next 2–6 months.
Read all positive factors
Clinica Baviera (CBAV) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€896.69M
Dividend Yield3.31%
Average Volume (3M)2.20K
Price to Earnings (P/E)19.7
Beta (1Y)0.56
Revenue Growth11.61%
EPS Growth7.67%
CountryES
Employees1,706
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.69
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio3.04
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.83
Revenue Forecast (FY)€330.20M
Clinica Baviera Business Overview & Revenue Model
Company Description
Clínica Baviera, S.A., a healthcare provider, manages a substantial chain of ophthalmological centers. This organization dedicates itself to the comprehensive diagnosis, therapeutic intervention, and continuous monitoring of diverse ocular conditi...
How the Company Makes Money
Clinica Baviera primarily makes money by delivering fee-based ophthalmology services through its clinics. Its main revenue streams come from (1) elective refractive vision-correction procedures (e.g., laser vision correction and lens-based refract...
Clinica Baviera Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
74
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 308.54M | 301.78M | 262.65M | 224.92M | 198.45M | 172.73M |
| Gross Profit | 251.94M | 127.08M | 232.08M | 197.85M | 172.95M | 151.25M |
| EBITDA | 86.76M | 106.14M | 78.11M | 67.22M | 56.15M | 53.49M |
| Net Income | 44.77M | 42.06M | 40.20M | 35.97M | 29.52M | 27.39M |
Balance Sheet | ||||||
| Total Assets | 263.87M | 247.51M | 211.95M | 178.64M | 150.10M | 133.81M |
| Cash, Cash Equivalents and Short-Term Investments | 64.83M | 50.32M | 38.58M | 51.24M | 38.99M | 32.27M |
| Total Debt | 68.15M | 69.16M | 63.47M | 47.41M | 47.81M | 51.56M |
| Total Liabilities | 138.35M | 136.55M | 113.59M | 86.37M | 81.74M | 78.42M |
| Stockholders Equity | 124.25M | 109.99M | 96.92M | 91.00M | 67.34M | 54.60M |
Cash Flow | ||||||
| Free Cash Flow | 45.07M | 46.47M | 36.25M | 35.13M | 39.35M | 36.28M |
| Operating Cash Flow | 75.74M | 76.48M | 62.76M | 57.81M | 53.38M | 46.86M |
| Investing Cash Flow | -15.34M | -27.88M | -20.90M | -44.31M | -12.56M | -17.08M |
| Financing Cash Flow | -36.13M | -36.10M | -39.91M | -24.37M | -31.45M | -30.80M |
Clinica Baviera Technical Analysis
Neutral
47.30
Price Trends
54.19
Positive
52.08
Positive
48.01
Positive
Market Momentum
0.49
Positive
47.61
Neutral
10.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Neutral. The current price of 47.3 is below the 20-day moving average (MA) of 56.13, below the 50-day MA of 54.19, and below the 200-day MA of 48.01, indicating a neutral trend. The MACD of 0.49 indicates Positive momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 10.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ES:CBAV.
Clinica Baviera Peers Comparison
UnderperformOutperform
Sector (51)
ES:CBAV
Clinica Baviera
56.00
17.73
46.34%
ES:ALM
Almirall
11.12
0.58
5.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.